Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer.
CCL5
breast cancer
cytokine
immunity
prognosis
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
19
06
2019
revised:
10
10
2019
accepted:
25
10
2019
pubmed:
15
11
2019
medline:
14
1
2020
entrez:
15
11
2019
Statut:
ppublish
Résumé
Analysis of anticancer immunity aids in assessing the prognosis of patients with breast cancer. From 250 operated breast cancers, we focused on serum levels of C-C motif chemokine ligand 5 (CCL5), which is involved in cancer immune reactions. Serum levels of CCL5 were measured using a cytometric bead-based immunoassay kit and CCL5 expression in cancer cells was determined using immunohistochemical staining. In addition, mRNA in cancer and stromal cells was analyzed by microdissection and comparison with the public dataset. Disease-free survival (DFS) of patients with high CCL5 levels (cut-off, 13.87 ng/mL; n = 192) was significantly better than those with low CCL5 levels (n = 58; hazard ratio, 0.20; 95% confidence interval, 0.10-0.39; P < .0001). An improved overall survival was observed in patients with high CCL5 levels compared to those with low CCL5 levels (P = .024). On the contrary, high immunohistochemical expression of CCL5 in cancer cells was significantly associated with decreased DFS. As serum CCL5 levels did not correlate with CCL5 expression in cancer cells and the relative expression of mRNA CCL5 was elevated in stromal cells in relation to cancer cells, serum CCL5 might be derived not from cancer cells, but from stromal cells. Expression of CCL5 in serum, but not in cancer cells, might contribute to improved patient prognosis mediating through not only immune reaction, but through other mechanisms. Determination of circulating CCL5 levels could be useful for predicting patient prognosis.
Identifiants
pubmed: 31724785
doi: 10.1111/cas.14234
pmc: PMC6942441
doi:
Substances chimiques
Biomarkers, Tumor
0
CCL5 protein, human
0
Chemokine CCL5
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209-218Subventions
Organisme : Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : No. 15K10077
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Immunotargets Ther. 2015 Aug 05;4:159-71
pubmed: 27471721
Int J Oncol. 2013 Feb;42(2):478-506
pubmed: 23254957
Oncoimmunology. 2013 Apr 1;2(4):e23660
pubmed: 23734321
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Mini Rev Med Chem. 2015;15(13):1063-72
pubmed: 26420723
Exp Cell Res. 2015 Oct 15;338(1):22-31
pubmed: 26363360
Genome Biol. 2006;7(12):243
pubmed: 17201934
Horm Cancer. 2013 Jun;4(3):140-53
pubmed: 23479404
Clin Cancer Res. 2015 Aug 15;21(16):3794-805
pubmed: 25901081
Clin Vaccine Immunol. 2011 Feb;18(2):210-6
pubmed: 21177916
Mol Cell Proteomics. 2009 Jun;8(6):1278-94
pubmed: 19329653
Pathology. 2017 Feb;49(2):141-155
pubmed: 28049579
Int J Nanomedicine. 2018 Jun 28;13:3795-3803
pubmed: 29988769
Br J Cancer. 2015 Mar 17;112(6):1088-97
pubmed: 25688736
Semin Cancer Biol. 2018 Oct;52(Pt 2):178-188
pubmed: 29104025
Biochim Biophys Acta. 2014 Apr;1845(2):182-201
pubmed: 24440852
J Immunol. 2013 May 15;190(10):5329-36
pubmed: 23589623
Biochem Biophys Res Commun. 2013 Sep 27;439(3):384-9
pubmed: 23998932
BMC Cancer. 2015 Dec 29;15:1027
pubmed: 26715527
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Oncotarget. 2018 Apr 3;9(25):17543-17553
pubmed: 29707128
Mol Immunol. 2002 May;38(12-13):881-5
pubmed: 12009564
PLoS One. 2016 Apr 13;11(4):e0152500
pubmed: 27073890
Oncotarget. 2016 Dec 20;7(51):85437-85449
pubmed: 27863423
Cell Res. 2013 Mar;23(3):394-408
pubmed: 23266888
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Biochem Biophys Rep. 2015 Nov 27;5:1-7
pubmed: 28955801
Nature. 2007 Oct 4;449(7162):557-63
pubmed: 17914389
Cancer Sci. 2020 Jan;111(1):209-218
pubmed: 31724785
Mol Cell Biol. 2007 Jan;27(1):253-66
pubmed: 17074812
Cancer Res. 2015 Oct 15;75(20):4312-21
pubmed: 26249173
Mol Cell Endocrinol. 2014 Jan 25;382(1):673-682
pubmed: 23791814
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Curr Top Microbiol Immunol. 2006;302:63-122
pubmed: 16620026
Oncotarget. 2016 Apr 26;7(17):24495-509
pubmed: 27027351
Int J Surg. 2016 Aug;32:136-42
pubmed: 27398691
Breast Cancer Res Treat. 2008 Oct;111(3):511-21
pubmed: 17978871
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Sci Rep. 2018 Mar 20;8(1):4899
pubmed: 29559701
Oncotarget. 2019 Jul 08;10(43):4356-4368
pubmed: 31320990
Biochem Biophys Res Commun. 2017 Aug 19;490(2):521-527
pubmed: 28624449
J Exp Med. 1994 May 1;179(5):1689-94
pubmed: 7513016
J Immunol. 1993 Sep 1;151(5):2601-12
pubmed: 7689610
Curr Opin Genet Dev. 2008 Feb;18(1):11-8
pubmed: 18308558
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Breast Cancer Res. 2017 Jan 5;19(1):2
pubmed: 28057046
Onco Targets Ther. 2016 Sep 08;9:5567-75
pubmed: 27660475
Breast Cancer Res Treat. 2018 Feb;168(1):135-145
pubmed: 29168063